Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer

Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancerBeyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer, Published online: 18 December 2018; doi:10.1038/s41571-018-0145-5Women with early-stage oestrogen receptor (ER)-positive (ER+) breast cancer remain at risk of distant recurrence for at least 15 years after discontinuation of 5 years of standard endocrine therapy. The authors of this Review discuss the epidemiology and mechanisms underlying late recurrence and examine several models used for risk prognostication and for estimating the presence of minimal residual disease.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research